Results 11 to 20 of about 22,643,381 (355)
Venous Thromboembolism Prophylaxis in Hemophilic Patients Undergoing Total Hip or Knee Arthroplasty: Insights from a Single-Center Experience [PDF]
MedicinaBackground and Objectives: Total hip replacement and total knee arthroplasty carry a high risk of postoperative venous thromboembolism (VTE); therefore, anticoagulation prophylaxis is recommended in these patients.
Oana-Viola Badulescu +13 more
doaj +2 more sources
Hemophilia in pediatric age [PDF]
Romanian Journal of Pediatrics, 2023 Hemophilia represents the most common inherited bleeding disorder linked to the X chromosome, which, if not properly treated, can lead to lifelong disabilities.
Cristina Elena Singer +7 more
doaj +1 more source
HEMATURIA IN HEMOPHILIA: WHAT DO WE KNOW? A CHALLENGING CASE STUDY AND LITERATURE REVIEW [PDF]
Euromediterranean Biomedical Journal, 2022 Hemophilia is a genetically determined bleeding disorder, which, if not properly managed, can cause lifelong disabilities. Hemorrhages in the joints and soft tissues are largely studied.
Alessandra Di Nora
doaj +1 more source
Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
New England Journal of Medicine, 2023 BACKGROUND Efanesoctocog alfa provides high sustained factor VIII activity by overcoming the von Willebrand factor-imposed half-life ceiling. The efficacy, safety, and pharmacokinetics of efanesoctocog alfa for prophylaxis and treatment of bleeding ...
Annette von Drygalski +14 more
semanticscholar +1 more source
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
New England Journal of Medicine, 2023 BACKGROUND Valoctocogene roxaparvovec delivers a B-domain-deleted factor VIII coding sequence with an adeno-associated virus vector to prevent bleeding in persons with severe hemophilia A.
J. Mahlangu +28 more
semanticscholar +1 more source
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
New England Journal of Medicine, 2022 BACKGROUND Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is an adeno-associated virus 5 (AAV5)-based gene-therapy vector containing a coagulation factor VIII complementary DNA driven by a liver-selective promoter.
M. Ozelo +22 more
semanticscholar +1 more source
Science Advances, 2022 Hemophilia is a hereditary disease that remains incurable. Although innovative treatments such as gene therapy or bispecific antibody therapy have been introduced, substantial unmet needs still exist with respect to achieving long-lasting therapeutic ...
J. Han +18 more
semanticscholar +1 more source
Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
Research and Practice in Thrombosis and Haemostasis, 2022 Emicizumab is a subcutaneously administered humanized, bispecific, monoclonal antibody approved for prophylaxis in people with hemophilia A.
Renchi Yang +11 more
semanticscholar +1 more source
Emicizumab-induced photosensitivity
TH Open, 2022 Emicizumab constitutes a novel and effective prophylaxis for hemophilia A patients with and without inhibitors. In this case report, we describe an emicizumab-induced photosensitivity that forced permanent sun-exposure suppression.
Pedro Asensi Cantó +6 more
doaj +1 more source